Advertisement

Topics

5-Fluoro-2-Deoxycytidine and Tetrahydrouridine in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndromes

2014-08-27 03:16:58 | BioPortfolio

Summary

RATIONALE: 5-Fluoro-2'-deoxycytidine (FdCyd) may inhibit cancer cell growth by increasing the production in cells of compounds that suppress growth or by otherwise killing cells. Although FdCyd is stable as a drug solution, it is rapidly inactivated by an enzyme present in people. Tetrahydrouridine (THU) is included in the treatment to inhibit the enzyme, prolonging the time FdCyd remains in the body.

PURPOSE: This randomized phase II trial is studying two different schedules of FdCyd to compare how well they work when given together with THU in treating patients with acute myeloid leukemia or myelodysplastic syndromes.

Description

OBJECTIVES:

I. Conduct a safety lead-in to refine the dose of FdCyd to be used in patients with Acute Myelogenous Leukemia (AML) and Myelodysplastic Syndrome (MDS) on each of two schedules (see Treatment Schema) to be used in the Phase II portion of the protocol.

II. To determine the anti-tumor activity of FdCyd and THU on two different schedules, as assessed by the objective response rate.

III. Evaluate time to treatment failure and survival in subjects with relapsed/refractory AML, relapsed/refractory or newly diagnosed MDS at int-1 or greater, or newly diagnosed AML patients over the age of 60.

IV. Evaluate whether treatment with FdCyd and THU alters DNA methylation patterns in peripheral blood mononuclear cells, including malignant myeloid cells, by analysis of LINE-1 methylation.

V. Determine the ratio of gamma to beta-globin mRNA by RT-PCR in blood cells before and after therapy as a marker of drug effect.

VI. To determine the changes in cytokines in the circulating blood and marrow before and after treatment with FdCyd and THU.

OUTLINE: Patients are randomized to 1 of 2 treatment arms.

ARM I: Patients receive FdCyd IV over 3 hours and THU IV over 3 hours on days 1-5 and 15-19. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.

ARM II: Patients receive FdCyd IV over 3 hours and THU IV over 3 hours on days 1-5 and 8-12. Courses repeat every 21days in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed periodically.

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Conditions

Adult Acute Myeloid Leukemia

Intervention

5-fluoro-2-deoxycytidine, tetrahydrouridine, laboratory biomarker analysis, reverse transcriptase-polymerase chain reaction, DNA methylation analysis

Location

City of Hope
Duarte
California
United States
91010

Status

Recruiting

Source

City of Hope Medical Center

Results (where available)

View Results

Links

Published on BioPortfolio: 2014-08-27T03:16:58-0400

Clinical Trials [2369 Associated Clinical Trials listed on BioPortfolio]

5-Fluoro-2'-Deoxycytidine and Tetrahydrouridine in Treating Patients With Advanced Solid Tumors

RATIONALE: Drugs used in chemotherapy, such as 5-fluoro-2'-deoxycytidine and tetrahydrouridine, work in different ways to stop the growth of tumor cells, either by killing the cells or by ...

A Multi-Histology Phase II Study of 5-Fluoro-2-Deoxycytidine With Tetrahydrouridine (FdCyd + THU)

Background: - Two experimental drugs, FdCyd (also called 5-fluoro-2'-deoxcytidine), and THU (also called tetrahydrouridine), are undergoing trials to test their effectiveness in ...

Tumor Angiogenesis in Patients With Endocrine Tumors

RATIONALE: Studying samples of tissue from patients with endocrine tumors in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to c...

Response or Resistance to Chemotherapy in Young Patients With Acute Lymphoblastic Leukemia Treated With Methotrexate

RATIONALE: Studying samples of tumor tissue in the laboratory from patients with cancer may help doctors learn more about changes that occur in DNA and drug resistance in patients. PURPOS...

Studying Tumor Tissue Samples From Patients With Soft Tissue Sarcoma

RATIONALE: Studying samples of tumor tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cance...

PubMed Articles [18270 Associated PubMed Articles listed on BioPortfolio]

Title: Once-weekly Oral Dosing of MK-8591 Protects Male Rhesus Macaques from Intrarectal SHIV109CP3 Challenge.

MK-8591 (4'-ethynyl-2-fluoro-2'-deoxyadenosine, EFdA) is a novel reverse transcriptase translocation inhibitor.

Assessment of fHbp Expression Level by Reverse Transcriptase Quantitative PCR and Promoter Sequence Analysis.

Reverse transcriptase quantitative PCR (RT qPCR) is widely used for assessing the levels of expression of specific genes in various organisms. Here we describe a RT qPCR assay designed to determine th...

Evaluation of 5-Ffluoro-2'-deoxycytidine as a tumor imaging agent: A comparison of FFdUrd, FFLT and FFDG.

One of the hallmarks of cancer is increased cell proliferation. Measurements of cell proliferation by estimation of DNA synthesis with several radiolabeled nucleosides have been tested to assess tumor...

Nucleoside reverse transcriptase inhibitor backbones and pregnancy outcomes.

The aim of this study was to investigate whether specific nucleoside reverse transcriptase inhibitor (NRTI) backbones are associated with risk of adverse pregnancy outcomes among pregnant women starti...

Non-nucleoside reverse transcriptase inhibitor efavirenz activates PXR to induce hypercholesterolemia and hepatic steatosis.

The most prescribed non-nucleoside reverse transcriptase inhibitor efavirenz has been associated with elevated risk for dyslipidemia and hepatic steatosis in HIV-infected patients but the underlying m...

Medical and Biotech [MESH] Definitions

A deoxycytidine analog and REVERSE TRANSCRIPTASE INHIBITOR with antiviral activity against HIV-1 and HEPATITIS B viruses. It is used to treat HIV INFECTIONS.

DNA sequences that form the coding region for retroviral enzymes including reverse transcriptase, protease, and endonuclease/integrase. "pol" is short for polymerase, the enzyme class of reverse transcriptase.

Inhibitors of reverse transcriptase (RNA-DIRECTED DNA POLYMERASE), an enzyme that synthesizes DNA on an RNA template.

A reverse transcriptase encoded by the POL GENE of HIV. It is a heterodimer of 66 kDa and 51 kDa subunits that are derived from a common precursor protein. The heterodimer also includes an RNAse H activity (RIBONUCLEASE H, HUMAN IMMUNODEFICIENCY VIRUS) that plays an essential role the viral replication process.

Retroviral proteins coded by the pol gene. They are usually synthesized as a protein precursor (POLYPROTEINS) and later cleaved into final products that include reverse transcriptase, endonuclease/integrase, and viral protease. Sometimes they are synthesized as a gag-pol fusion protein (FUSION PROTEINS, GAG-POL). pol is short for polymerase, the enzyme class of reverse transcriptase.

More From BioPortfolio on "5-Fluoro-2-Deoxycytidine and Tetrahydrouridine in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndromes"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Cancer Disease
Cancer is not just one disease but many diseases. There are more than 100 different types of cancer. Most cancers are named for the organ or type of cell in which they start - for example, cancer that begins in the colon is called colon cancer; cancer th...

Pharmacy
Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...


Searches Linking to this Trial